Pfenex Priced, NYSE American: PFNX
Developing a biosimilar version of Roche's Lucentis treatment for wet AMD.
Industry: Health Care
First Day Return: -11.7%
Industry: Health Care
PFNX
Developing a biosimilar version of Roche's Lucentis treatment for wet AMD.
| IPO Data | |
|---|---|
| IPO File Date | 06/05/2014 |
| Offer Price | $6.00 |
| Price Range $8.00 - $8.00 | |
| Offer Shares (mm) | 8.3 |
| Deal Size ($mm) | $50 |
| Lock-Up Date | IPO Pro Only |
| Street Research | IPO Pro Only |
| IPO Data | |
|---|---|
| IPO Date | 07/23/2014 |
| Offer Price | IPO Intelligence Only |
| Price Range | IPO Intelligence Only |
| Offer Shares (mm) | IPO Intelligence Only |
| Deal Size ($mm) | $50 |
| Lock-Up Date | IPO Intelligence Only |
| Street Research | IPO Intelligence Only |
| Underwriters |
|---|
| IPO Intelligence Only |
| Company Data | |
|---|---|
| Headquarters | San Diego, CA, United States |
| Founded | 2009 |
| Employees at IPO | 25 |
| Website www.pfenex.com | |
Pfenex (PFNX) Performance
